原发性肾癌热消融后挽救性立体定向消融体部放疗
多机构回顾性分析纳入17例热消融后复发肾细胞癌患者共18个活检确认病灶,评估挽救性SABR的疗效与安全性。中位随访3.36年,局部控制率100%,3年远处无进展生存72.1%、肿瘤特异性生存92.3%、总生存82.1%,无3级以上毒性或终末期肾病。SABR似乎是热消融后复发RCC有效且安全的挽救策略。
要点
- 热消融后复发RCC接受挽救性SABR,局部控制率100%,无局部进展。
- 3年远处无进展生存72.1%、肿瘤特异性生存92.3%、总生存82.1%。
- 无3级以上毒性或终末期肾病,肾小球滤过率中位由58降至48 mL/min。
核心结论
- 结果表明,SABR似乎是热消融后复发肾细胞癌患者有效且安全的挽救策略。
研究设计与样本
- 本研究为多机构回顾性分析,纳入2016年至2020年间热消融后复发肾细胞癌并接受SABR的患者。
- 共纳入17例患者、18个活检确认的肾细胞癌病灶。
- 主要结局为基于RECIST v1.1影像评估的局部无失败率,次要结局包括远处失败、肿瘤特异性生存、总生存、治疗相关毒性和肾功能变化。
主要发现
- SABR时中位(IQR)年龄为75.2(72.6-68.7)岁,中位(IQR)肿瘤大小为3.5(1.9-4.1)cm,随访(反向Kaplan-Meier法)为3.36(95%CI 1.6-4.1)年。
- 17例患者中6例为孤立肾,5例在SABR前重复热消融失败,热消融至SABR的中位(IQR)时间为3.03(1.5-5.1)年。
- 无患者出现局部进展,局部控制率为100%;4例患者出现远处进展,其中2例基线即有转移性疾病。
- 3年远处无进展生存为72.1%(95%CI 51.9%-100%),肿瘤特异性生存为92.3%(95%CI 78.9%-100%),总生存为82.1%(95%CI 62.1%-100%)。
- SABR前中位(IQR)肾小球滤过率为58(40-71)mL/min,末次随访时为48(33-57)mL/min;无患者出现3级以上毒性或进展为终末期肾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA). MATERIALS AND METHODS: This study was a multi-institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer-specific survival (CSS), overall survival (OS), treatment-related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan-Meier method was used to estimate freedom from local and distant failure, CSS and OS. RESULTS: Seventeen patients with 18 biopsy-confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6-68.7) years, a median (IQR) tumour size of 3.5 (1.9-4.1) cm and follow-up (reverse Kaplan-Meier method) of 3.36 (95% confidence interval [CI] 1.6-4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5-5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression-free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%-100%), 92.3% (95% CI 78.9%-100%) and 82.1% (95% CI 62.1%-100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40-71) mL/min, and at last follow-up, it was 48 (33-57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end-stage renal disease. CONCLUSION: The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.
引用
- Ali M, Kwon YS, Koo K, et al. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. BJU Int. 2024. PMID: 39187428. doi:10.1111/bju.16520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。